Ignite Creation Date:
2024-07-17 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06489821
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2023-11-16
Brief Title:
STereotactic Body Radiotherapy SBRT for Oligoprogressive Breast Cancer
Sponsor:
Juravinski Cancer Center
Organization:
Juravinski Cancer Center
Study Overview
Official Title:
STereotactic Body Radiotherapy SBRT After oligoprogRession Metastatic Breast Cancer STAR-B
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STAR-B
Brief Summary:
Recent advances in systemic therapy have facilitated improved progression-free survival PFS and treatment tolerability in metastatic breast cancer patients MBC Oligoprogression OP refers to progression limited to five or fewer sites in otherwise controlled systemic disease on a drug therapy Stereotactic body radiotherapy SBRT has the potential to locally ablate resistant OP lesions that develop on a systemic treatment and may consequently delay the need for change in drug therapy delay time to chemotherapy and prolong PFS This is a phase II trial of SBRT plus continuation of current systemic therapy line for OP MBC patients to determine rate of delay of change in systemic therapy of at six months PFS time to chemotherapy and quality of life will also be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None